SCOTTSDALE, Ariz., May 31, 2012 /PRNewswire/ -- Kowa Pharmaceuticals America, Inc. and Eli Lilly and Company (NYSE:LLY) today announced results of the PREVAIL U.S.

Weight loss improved both metabolic parameters and sleep-disordered breathing (SDB) in obese children in a new study from researchers in Belgium.

High-density lipoprotein, otherwise known as HDL, was thought to be “good” cholesterol. However, a new study, based on databases of genetic information, disproves the HDL theory and states that rising HDL may not have any change to heart disease risk.

A new paper published online in The Lancet challenges the assumption that raising a person's HDL — the so-called "good cholesterol" — will necessarily lower the risk of a heart attack.

CARLSBAD, Calif., May 4, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc.